Regulatory
Track how regulatory decisions alter competitive positioning, launch timelines, and investor expectations across therapeutic areas.
3 signals
REGULATORY
The EU CHMP has issued a positive opinion for the combination of KEYTRUDA and Padcev as a treatment for cisplatin-ineligible muscle-invasive bladder cancer.
REGULATORY
The FDA has accepted Roche's sBLA for Tecentriq in combination with chemotherapy for stage III dMMR/MSI-H colon cancer, with a decision expected by October 9, 2026.
REGULATORY
Enhertu has been recommended for approval by the CHMP for patients with previously treated HER2-positive metastatic solid tumours.
Showing 1–3 of 3 records
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.